10 recruiting, 7 active not recruiting, 3 not yet recruiting, 1 completed. 6 Phase 3, 4 Phase 2, 3 Not applicable.
Follow Progressive Pulmonary Fibrosis: new trials by email Literature Review of Progressive Pulmonary Fibrosis trials Research Report on Progressive Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) Treprostinil Palmitil Inhalation Powder, Placebo - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Not yet recruiting | Insmed Incorporated | 800 | 2026-12-01 | 2026-09-04 |
| Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Completed | Boehringer Ingelheim | 122 | 2026-08-01 | 2026-10-13 | |
| Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis Antifibrotic therapy - Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-08-01 | 2026-07-23 | |
| Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis HSK44459, Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 378 | 2026-04-05 | 2026-03-31 |
| Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases. standard interview - Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) | Active not recruiting | Istituto Clinico Humanitas | 1000 | 2026-04-01 | 2026-05-11 | |
| Hereditary Influences on Pulmonary Fibrosis Trajectories Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF) | Active not recruiting | Istituto Clinico Humanitas | 250 | 2026-04-01 | 2026-05-12 | |
| Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit - Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease | Not applicable | Active not recruiting | Hospital de Granollers | 152 | 2026-03-09 | 2026-10-21 |
| Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. Quercetin (dietary supplement), Usual treatment - Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF) | Not applicable | Recruiting | Katerina M. Antoniou | 100 | 2026-01-26 | 2026-03-12 |
| Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease Dual-site pulse oximetry (finger and earlobe) - Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF) | Recruiting | Hospital de Granollers | 100 | 2026-01-13 | 2026-07-23 | |
| SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers SUPPORT-T Educational Intervention - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Not applicable | Recruiting | Medical University of South Carolina | 170 | 2026-01-13 | 2026-09-11 |
| Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 60 | 2026-01-10 | 2026-09-15 | |
| A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA) Progressive Pulmonary Fibrosis | Recruiting | Zuojun Xu | 600 | 2025-09-23 | 2026-07-06 | |
| A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications No Interventions, No intervention - Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis | Recruiting | Royal Brompton & Harefield NHS Foundation Trust | 30 | 2025-09-09 | 2026-01-12 | |
| PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Recruiting | University of Massachusetts, Worcester | 500 | 2025-05-01 | 2026-08-18 | |
| An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) AP01 - Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 340 | 2025-04-17 | 2026-10-02 |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Nerandomilast - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Boehringer Ingelheim | 1666 | 2024-09-26 | 2026-10-14 |
| A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis BI 1839100, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Terminated | Boehringer Ingelheim | 85 | 2024-08-28 | 2026-09-23 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis AP01, Placebo - Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Avalyn Pharma Inc. | 398 | 2024-04-03 | 2026-10-16 |
| Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer - Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Recruiting | United Therapeutics | 698 | 2023-10-30 | 2026-07-13 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis BMS-986278, BMS-986278 Placebo - Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 1057 | 2023-10-25 | 2026-04-23 |
Showing 20 of 23. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (15) · Lung Diseases, Interstitial (12) · Pulmonary Fibrosis (5) · Alveolitis, Extrinsic Allergic (2) · Arthritis, Rheumatoid (1) · Connective Tissue Diseases (1) · Fibrosis (1) · Sarcoidosis (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1)
Lung Diseases (21) · Respiratory Tract Diseases (21) · Pulmonary Fibrosis (12) · Lung Diseases, Interstitial (9) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Fibrosis (4) · Hypersensitivity (3) · Immune System Diseases (3) · Hypersensitivity, Immediate (2) · Respiratory Hypersensitivity (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Arthritis (1) · Autoimmune Diseases (1)
treprostinil (2) · BI 1015550 (1) · Dietary Supplements (1) · Quercetin (1) · nintedanib (1)
Boehringer Ingelheim (3) · Avalyn Pharma Inc. (2) · Bristol-Myers Squibb (2) · Hospital de Granollers (2) · Istituto Clinico Humanitas (2) · United Therapeutics (2) · Duke University (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Insmed Incorporated (1) · Katerina M. Antoniou (1) · Medical University of South Carolina (1) · Pulmonary Fibrosis Foundation (1) · Royal Brompton & Harefield NHS Foundation Trust (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · University of Massachusetts, Worcester (1)
United States (11) · Italy (10) · Spain (9) · Australia (8) · Canada (8) · France (8) · Germany (8) · Netherlands (7) · United Kingdom (7) · Argentina (6) · Belgium (6) · New Zealand (6) · China (5) · Czechia (5) · Denmark (5)
Francesco Amati, MD (2) · Cathie Spino, DSc (1) · Dinesh Khanna, MD, MS (1) · Fernando J Martinez, MD, MS (1) · Imre Noth, MD, MS (1) · Jaume Bordas-Martinez, M.D., Ph.D. (1) · Jaume Bordas-Martinez, MD, PhD (1) · Justin Oldham, MD, MS (1) · Katerina M. Antoniou, MD PhD, Professor (1) · Luca Richeldi, MD, PhD (1) · Michael Kreuter, MD (1) · Robert M Tighe, MD (1)
PMID 36948586, PMID 41345848, PMID 41448793, PMID 42548323
2023 (3)